A. Menarini Industrie Farmaceutiche Riunite has been granted a patent for cancer stem cell targeted cancer vaccines and methods for treating and vaccinating against cancer. The patent includes regimens for administering the vaccines, patient populations, dosages, schedules, and routes of administration. The patent also claims a specific method for treating brain cancer using a pharmaceutical composition containing specific peptides and bevacizumab. GlobalData’s report on A. Menarini Industrie Farmaceutiche Riunite gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on A. Menarini Industrie Farmaceutiche Riunite, cancer treatment biomarkers was a key innovation area identified from patents. A. Menarini Industrie Farmaceutiche Riunite's grant share as of June 2023 was 1%. Grant share is based on the ratio of number of grants to total number of patents.
Cancer stem cell targeted cancer vaccine for brain cancer
A recently granted patent (Publication Number: US11672847B2) describes a method for treating brain cancer in human subjects. The method involves administering a pharmaceutical composition to the subject, which includes specific peptides and a tetanus toxoid peptide. The composition is formulated as an emulsion and is co-administered with bevacizumab, a commonly used cancer drug.
In one embodiment of the method, the pharmaceutical composition is administered subcutaneously. The composition includes peptides such as IL-13Ra2, EphA2, survivin, and a tetanus toxoid peptide. These peptides have specific amino acid sequences mentioned in the patent.
Another embodiment of the method involves administering the pharmaceutical composition along with one or more immunomodulatory agents. These agents help polarize the immune response of the subject towards a Th1 response, which is beneficial in treating brain cancer. The composition is emulsified using Montanide ISA-51, and the immunomodulatory agents can be nucleic acid molecules or toll-like receptor (TLR) agonists, such as TLR3 agonist or imiquimod. Additionally, the composition can include GM-CSF, a growth factor that stimulates the production of white blood cells.
The patent also describes a combination therapy for treating brain cancer. This method involves administering three separate pharmaceutical compositions to the subject. The first composition includes the peptides mentioned earlier, formulated as an emulsion. The second composition includes GM-CSF, and the third composition includes imiquimod. All three compositions are co-administered with bevacizumab.
The method is applicable to subjects who are in remission, have undergone a relapse, or have received prior treatments that failed. It can also be combined with other cancer therapies for enhanced effectiveness.
Overall, this granted patent presents a method for treating brain cancer using a specific pharmaceutical composition and combination therapy. The method aims to improve the treatment outcomes for brain cancer patients, particularly those who have not responded well to previous treatments.
To know more about GlobalData’s detailed insights on A. Menarini Industrie Farmaceutiche Riunite, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
